Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunityBio, Inc.NK · Entity 3618 | Director | June 09, 2017 | June 13, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunityBio, Inc.
Report date June 09, 2017 · Filed June 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,253 |
Reported balance
After 2017-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-06-09 · Grant · Acquired 23,753 · Balance 159,253 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the one year anniversary of the vesting commencement date on the same day of the month as the vesting commencement date. The vesting commencement date for this award is June 9, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock.
F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the one year anniversary of the vesting commencement date on the same day of the month as the vesting commencement date. The vesting commencement date for this award is June 9, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2017 Filed Jun 13, 2017 20:13 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 23,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039435 · doc4.xml · nonDerivative · entry 1 POTTS JOHN T JR · CIK 0001202447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,253 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the one year anniversary of the vesting commencement date on the same day of the month as the vesting commencement date. The vesting commencement date for this award is June 9, 2017. Read SEC document |
| August 03, 2016 Filed Feb 14, 2017 01:49 UTC | ImmunityBio, Inc. NK · Entity 3618 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010246 · doc5.xml · nonDerivative · entry 2 POTTS JOHN T JR · CIK 0001202447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,500 Read SEC document |
| August 02, 2016 Filed Feb 14, 2017 01:49 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 135,500 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001209191-17-010246 · doc5.xml · derivative · entry 3 POTTS JOHN T JR · CIK 0001202447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 Underlying: Common Stock · 135,500 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is March 17, 2014. Read SEC document |
| August 02, 2016 Filed Feb 14, 2017 01:49 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 135,500 | $0.22 | $29,281.55 |
DisclosureSEC source: 0001209191-17-010246 · doc5.xml · nonDerivative · entry 1 POTTS JOHN T JR · CIK 0001202447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.